» Articles » PMID: 38969706

IRF5 Suppresses Metastasis Through the Regulation of Tumor-derived Extracellular Vesicles and Pre-metastatic Niche Formation

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jul 5
PMID 38969706
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis is driven by extensive cooperation between a tumor and its microenvironment, resulting in the adaptation of molecular mechanisms that evade the immune system and enable pre-metastatic niche (PMN) formation. Little is known of the tumor-intrinsic factors that regulate these mechanisms. Here we show that expression of the transcription factor interferon regulatory factor 5 (IRF5) in osteosarcoma (OS) and breast carcinoma (BC) clinically correlates with prolonged survival and decreased secretion of tumor-derived extracellular vesicles (t-dEVs). Conversely, loss of intra-tumoral IRF5 establishes a PMN that supports metastasis. Mechanistically, IRF5-positive tumor cells retain IRF5 transcripts within t-dEVs that contribute to altered composition, secretion, and trafficking of t-dEVs to sites of metastasis. Upon whole-body pre-conditioning with t-dEVs from IRF5-high or -low OS and BC cells, we found increased lung metastatic colonization that replicated findings from orthotopically implanted cancer cells. Collectively, our findings uncover a new role for IRF5 in cancer metastasis through its regulation of t-dEV programming of the PMN.

Citing Articles

Pediatric cancer-pathology and microenvironment influence: a perspective into osteosarcoma and non-osteogenic mesenchymal malignant neoplasms.

Sergi C Discov Oncol. 2024; 15(1):358.

PMID: 39154307 PMC: 11330953. DOI: 10.1007/s12672-024-01240-5.

References
1.
OGrady T, Njock M, Lion M, Bruyr J, Mariavelle E, Galvan B . Sorting and packaging of RNA into extracellular vesicles shape intracellular transcript levels. BMC Biol. 2022; 20(1):72. PMC: 8944098. DOI: 10.1186/s12915-022-01277-4. View

2.
Pimenta E, Barnes B . A conserved region within interferon regulatory factor 5 controls breast cancer cell migration through a cytoplasmic and transcription-independent mechanism. Mol Cancer. 2015; 14:32. PMC: 4326371. DOI: 10.1186/s12943-015-0305-5. View

3.
Zhang Y . Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor. Pharmacol Rev. 2023; 75(6):1218-1232. PMC: 10595022. DOI: 10.1124/pharmrev.123.000906. View

4.
Roberts B, Collado G, Barnes B . Role of interferon regulatory factor 5 (IRF5) in tumor progression: Prognostic and therapeutic potential. Biochim Biophys Acta Rev Cancer. 2023; 1879(1):189061. DOI: 10.1016/j.bbcan.2023.189061. View

5.
Leifler K, Svensson S, Abrahamsson A, Bendrik C, Robertson J, Gauldie J . Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J Immunol. 2013; 190(8):4420-30. PMC: 3619527. DOI: 10.4049/jimmunol.1202610. View